




RealRate

PHARMACEUTICAL 2015

Bioxytran INC
Rank 270 of 274



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Bioxytran INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bioxytran INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 0.64% points. The greatest weakness of Bioxytran INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 157% points.

The company's Economic Capital Ratio, given in the ranking table, is 0.68%, being 253% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	6.2
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	335
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	166
Other Liabilities	0
Other Net Income	-66
Other Revenues	276
Property and Equipment	107
Research and Development	0
Selling, General and Administrative Expense	1,390

Output Variable	Value in 1000 USD
Assets	113
Liabilities	335
Expenses	1,556
Revenues	276
Stockholders Equity	-221
Net Income	-1,347
Comprehensive Net Income	-1,347
BaseVar	1,173
ECR before LimitedLiability	-817%
Economic Capital Ratio	0.68%